Published in J Clin Oncol on March 15, 2002
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2014) 1.20
A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med (2009) 1.18
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther (2013) 1.04
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs (2012) 1.02
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer (2003) 0.98
Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis (2008) 0.98
Productive replication of human adenovirus type 5 in canine cells. J Virol (2005) 0.97
Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res (2011) 0.97
A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol (2011) 0.96
New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther (2009) 0.95
A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice. Mol Ther (2012) 0.90
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol (2009) 0.90
Gene Therapy Applications to Cancer Treatment. J Biomed Biotechnol (2003) 0.90
The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. Gut (2015) 0.88
Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone (2006) 0.87
Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget (2013) 0.86
Gene therapy for gastric cancer: is it promising? World J Gastroenterol (2006) 0.86
Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol (2012) 0.86
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther (2011) 0.85
The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Res (2010) 0.84
Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. PLoS One (2011) 0.84
A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. Hum Reprod (2010) 0.84
Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials. Geburtshilfe Frauenheilkd (2012) 0.80
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus. Oncotarget (2014) 0.80
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol (2016) 0.79
Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virol (2013) 0.79
Oncolytic viruses: do they have a role in anti-cancer therapy? Clin Med Oncol (2008) 0.78
Oncolytic virotherapy for ovarian cancer. Oncolytic Virother (2012) 0.77
Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB (Oxford) (2007) 0.77
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther (2010) 0.76
Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models. Cancer Gene Ther (2015) 0.75
Regional delivery of oncolytic vaccinia virus: it's time for clinical trials. Ann Surg Oncol (2014) 0.75
Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Sci Rep (2017) 0.75
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Mol Ther Oncolytics (2016) 0.75
Gene transfer: Bax to the future for cancer therapy. Gut (2004) 0.75
Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites. Mol Ther Oncolytics (2017) 0.75
The genome of black cottonwood, Populus trichocarpa (Torr. & Gray). Science (2006) 21.03
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr (1997) 5.47
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res (2001) 4.15
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
Diaphragm function and alveolar hypoventilation. Q J Med (1976) 3.94
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Consensus statement on the live organ donor. JAMA (2000) 3.29
Effect of community-based interventions on high-risk drinking and alcohol-related injuries. JAMA (2000) 3.24
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal (1996) 3.18
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
A population of fast radio bursts at cosmological distances. Science (2013) 3.03
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood (1976) 2.76
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Brain spectrin, a membrane-associated protein related in structure and function to erythrocyte spectrin. Nature (1982) 2.74
Prospective study of outcome in antenatally diagnosed renal pelvis dilatation. Arch Dis Child Fetal Neonatal Ed (1999) 2.73
Fatal injuries to bicyclists: the experience of Dade County, Florida. J Trauma (1983) 2.73
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Perforating eye injuries: a five year survey. Trans Ophthalmol Soc U K (1971) 2.63
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
Ankyrin and spectrin associate with voltage-dependent sodium channels in brain. Nature (1988) 2.60
High-level expression of M13 gene II protein from an inducible polycistronic messenger RNA. Gene (1985) 2.56
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Fulminating vibrio parahemolyticus septicemia. A syndrome of erythemia multiforme, hemolytic anemia, and hypotension. Arch Intern Med (1974) 2.46
The role of superoxide anion and hydrogen peroxide in phagocytosis-associated oxidative metabolic reactions. J Clin Invest (1975) 2.40
High frequency of antimicrobial resistance in human fecal flora. Antimicrob Agents Chemother (1988) 2.30
Changes in bone mineral content in male athletes. Mechanisms of action and intervention effects. JAMA (1996) 2.29
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Discussions about the use of life-sustaining treatments: a literature review of physicians' and patients' attitudes and practices. End of Life Study Group. J Clin Ethics (1994) 2.25
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol (2005) 2.24
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Abnormalities of thyroid function in infants with Down syndrome. J Pediatr (1984) 2.19
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Interaction of spontaneous respiration with artificial ventilation in preterm babies. J Pediatr (1983) 2.11
Autooxidation as a basis for altered function by polymorphonuclear leukocytes. Blood (1977) 2.10
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol (2004) 2.08
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Urinary diagnosis of gonorrhoea and Chlamydia in men in remote aboriginal communities. Med J Aust (1997) 2.01
Transformation of a star into a planet in a millisecond pulsar binary. Science (2011) 2.01
Alterations of IgM, IgG, and IgA Synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology (1981) 1.98
Low-molecular- weight Rauscher leukemia virus protein with preferential binding for single-stranded RNA and DNA. J Virol (1976) 1.92
Visual cortical mechanisms detecting focal orientation discontinuities. Nature (1995) 1.92
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun (1992) 1.85
Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. Clin Pediatr (Phila) (2001) 1.81
Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet (2004) 1.80
Corrugator supercilii muscle resection and migraine headaches. Plast Reconstr Surg (2000) 1.79
Quantitative trait loci and candidate gene mapping of bud set and bud flush in populus. Genetics (2000) 1.76
The effect of a partially hydrolysed formula based on rice protein in the treatment of infants with cow's milk protein allergy. Pediatr Allergy Immunol (2010) 1.75
Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets (2003) 1.75
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Brain alpha-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron (1990) 1.72
DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A (2003) 1.71
Evaluation of nested polymerase chain methods for the detection of human coronaviruses 229E and OC43. Mol Cell Probes (1994) 1.70
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
Identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry (2009) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Infantile myofibromatosis: the most common fibrous tumor of infancy. J Pediatr Surg (1988) 1.67
Replication-selective adenoviruses as oncolytic agents. J Clin Invest (2000) 1.66
Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg (1991) 1.66
Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol (1977) 1.65
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Brain spectrin. Isolation of subunits and formation of hybrids with erythrocyte spectrin subunits. J Biol Chem (1983) 1.63
An isoform of ankyrin is localized at nodes of Ranvier in myelinated axons of central and peripheral nerves. J Cell Biol (1990) 1.63
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
A dual micro-CT system for small animal imaging. Proc SPIE Int Soc Opt Eng (2008) 1.62
The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Prenat Diagn (1996) 1.60
Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant (2009) 1.59
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol (1987) 1.58
First symptom in sporadic Creutzfeldt-Jakob disease. Neurology (2006) 1.58
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Nonproductive kappa immunoglobulin genes: recombinational abnormalities and other lesions affecting transcription, RNA processing, turnover, and translation. Mol Cell Biol (1985) 1.55
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Unified nomenclature for subunits of the Saccharomyces cerevisiae proteasome regulatory particle. Trends Biochem Sci (1998) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53
Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol (1998) 1.53
Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol (1979) 1.53